Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andreas Meisel
Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper
1 Introduction The therapeutic landscape of generalised myasthenia gravis (gMG) has undergone a remarkable transformation in recent years. For decades, treatment options beyond symptomatic and broad immunosuppressive approaches were limited. Now, several pivotal phase 3 trials have demonstrated robust efficacy of targeted immunotherapies, leading to successive regulatory approvals [1-7].
Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models
|
Abstract Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients.
By Niels von Wardenburg, Gregorio Spagni, S. Momsen Reincke, Hans-Christian Kornau, Marie A. Homeyer, Sonja Blumenau, Maria Stecklum, Dietmar Schmitz, Andreas Pelz, Valentina Damato, Nicholas Sanderson, Tobias Derfuss, Minh Pham, Kevin C. O’Connor, Andreas Meisel, Harald Prüss, Stephanie Wernick, Viktoria Zinnow, Amelya Keles Slevogt, Lucie Y. Li
|
Nature
Verified
A transcriptomic microglia taxonomy across mouse and human pathologies
|
Abstract Single-cell studies have revealed substantial microglial diversity in development, homeostasis and disease. However, a framework enabling comparison and stratification of microglial states across contexts is needed. Here we generated an atlas of myeloid cell states by single-cell RNA sequencing more than one million central nervous system cells from more than 30 physiological and pathological conditions.
By Chintan Chhatbar, Roman Sankowski, Michael Schulz, Takashi Shimizu, Marius Schwabenland, Ori Staszewski, Christian Scheiwe, Katharina Borst, Anaelle Aurelie Dumas, Wesley Brandao, Omar Mossad, Adrià Dalmau Gasull, Maximilian Frosch, Daniel Erny, Martin Diebold, Janaki Manoja Vinnakota, Koliane Ouk, Inken Waltl, Michael LaMorte, Timothy R. Hammond, Giovanni Di Liberto, Ilena Vincenti, Mario Kreutzfeldt, Ibrahim T Mughrabi, Yousef Al-Abed, Thomas Blank, Melanie Meyer-Luehmann, Yanick J. Crow, Dimitry Ofengeim, Robert Zeiser, Jutta Gärtner, Andreas Meisel, Martin Schwemmle, Ulrich Kalinke, Jürgen Beck, Bertram R Bengsch, Robert Thimme, Oleg Butovsky, Tamara Seredenina, Richard M. Ransohoff, Francisco J. Quintana, Katrin Kierdorf, Doron Merkler, Christine Stadelmann, Josef Priller, Marco Prinz, Stefan Nessler, Ella Trost, Daniel Berchtold, Elena Guffart, Katharina Ternka, Mihaela Guranda, Marina Friesen, Nellwyn Hagen, Matthias Kettwig
|
Nature
Verified
Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal
1 Introduction Generalized myasthenia gravis (MG) is a rare autoimmune disease characterized by antibody-driven damage to the neuromuscular junctions (NMJ), resulting in symptoms ranging from fluctuating activity-dependent weakness to life-threatening respiratory failure [1-3]. Given the absence of a cure for gMG, treatment focuses on symptom management through reduction of disease activity.
The economic burden of Myasthenia gravis from the patient´s perspective and reflected in German claims data - Scientific Reports
Abstract Myasthenia gravis (MG) is a neuromuscular disorder resulting in exertion-dependent muscle fatigability. Affecting all age groups MG is a chronic disease with unpredictable fluctuations and a range of symptom expression which can require costly immunosuppressive therapy and intensive care critically influencing economic burden. Here we aim to elucidate both the personal and societal economic burden of MG.
Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction - Nature Communications
|
Abstract Myasthenia gravis (MG) is a rare autoantibody-mediated disease affecting the neuromuscular junction. We performed a genome-wide association study of 5708 MG cases and 432,028 controls of European ancestry and a replication study in 3989 cases and 226,643 controls provided by 23andMe Inc. We identified 12 independent genome-wide significant hits (P < 5e−8) across 11 loci.
By Alice Braun, Sudhanshu Shekhar, Daniel F Levey, Julia Kraft, Maike Stein, Philipp Mergenthaler, Maria Koromina, Teemu Palviainen, Astros Th. Skuladottir, Ingileif Jónsdóttir, Kari Stefansson, Aarno Palotie, Frank Leypoldt, Murray B. Stein, Pierre Fontanillas, Jaakko Kaprio, Joel Gelernter, Lea K. Davis, Martijn R Tannemaat, Jan J.G.M. Verschuuren, Peter K. Gregersen, Maartje G. Huijbers, Frauke Stascheit, Andreas Meisel, Bergrun Asbjornsdottir
|
Nature
Verified
Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis
INTRODUCTION Advances in our understanding of myasthenia gravis (MG) pathophysiology have aided the development of targeted treatment approaches with the potential to provide faster therapeutic benefit than mainstay treatments such as non-steroidal immunosuppressive therapies (NSISTs), without the problematic side effects associated with broad immunosuppression.
The telemedical platform MyaLink for remote monitoring in myasthenia gravis: Rationale and protocol for a proof of concept study
M.S. has received speakers honoraria and honoraria for attendance at advisory boards from Argenx and Alexion. A.M. received speakers honoraria from Alexion, Grifols and Hormosan and honoria from Argenx, Alexion, MorphoSys and UCB for consulting services and financial research support from Alexion and Octapharma. He is chairperson of the medical advisory board of the DMG. P.N. received grant support from PCORI, Alexion, Dianthus, and Janssen.
Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis
INTRODUCTION Generalised myasthenia gravis (gMG) is a rare and chronic, immunoglobulin G (IgG)-mediated, neuromuscular autoimmune disease, which causes debilitating and potentially life-threatening muscle weakness [1, 2]. Most patients with myasthenia gravis (MG) first present with ocular symptoms only; however, approximately 80% will have gMG within 2 years of initial disease onset [2].
Are CAR T cells the answer to myasthenia gravis therapy?
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)
Discussion This analysis of baseline data from 1693 adults living with MG across seven countries revealed a moderate participant-reported burden, despite effective treatment being actively received. Reporting participants were likely to experience at least one of a wide range of comorbidities, alongside symptoms attributed to side effects such as tiredness and muscle twitches.
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Abstract Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating autoimmune disease. Activation of the complement system by autoantibodies against the postsynaptic acetylcholine receptor (AChR) leads to destruction of the postsynaptic membrane and disruption of neuromuscular transmission. This trial evaluated ravulizumab, a long-acting inhibitor of terminal complement protein C5, as a treatment for gMG.
Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis
VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis • Recent study showing that VNTR3 genotype matters with respect to the efficacy of IVIg in MG
Regulators of cholinergic signaling in disorders of the central nervous system
Katarzyna Winek Corresponding Author katarzyna.winek@mail.huji.ac.il orcid.org/0000-0003-3085-9054 The Edmond & Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel Correspondence Edmond J.
S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigue in the presence of circulating antibodies against components of the neuromuscular junction. Most patients have a good prognosis, but some are refractory to standard-of-care immunosuppressive treatment and suffer from recurrent myasthenic crises.
Depletion of Cultivatable Gut Microbiota by Broad-Spectrum Antibiotic Pretreatment Worsens Outcome After Murine Stroke
Background and Purpose—Antibiotics disturbing microbiota are often used in treatment of poststroke infections. A bidirectional brain–gut microbiota axis was recently suggested as a modulator of nervous system diseases. We hypothesized that gut microbiota may be an important player in the course of stroke. Methods—We investigated the outcome of focal cerebral ischemia in C57BL/6J mice after an 8-week decontamination with quintuple broad-spectrum antibiotic cocktail.
How Is Pneumonia Diagnosed in Clinical Stroke Research?
Background and Purpose—Diagnosis of pneumonia complicating stroke is challenging, and there are currently no consensus diagnostic criteria. As a first step in developing such consensus-based diagnostic criteria, we undertook a systematic review to identify the existing diagnostic approaches to pneumonia in recent clinical stroke research to establish the variation in diagnosis and terminology.
In-Hospital Stroke Recurrence and Stroke After Transient Ischemic Attack
Background and Purpose—We aimed to assess the risk of recurrent ischemic events during hospitalization for stroke or transient ischemic attack (TIA) with optimal current management and to identify associated risk factors. Methods—We performed a retrospective analysis of all patients treated for acute ischemic stroke or TIA in 3 stroke units between 2010 and 2013.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andreas
Contact Andreas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack